Answers are grounded in this paper and cite their sources.
Background HIV-1 drug resistance monitoring traditionally relies on Sanger sequencing of targeted pol regions. Whole genome sequencing (WGS) enables the detection of mutations in all coding regions, including minority variants and resistance-associated polymorphisms outside pol, which may impact treatment with novel antiretrovirals. Objectives To evaluate the clinical performance of a CE-IVD certified HIV-1 WGS kit (DeepChek®, ABL SA) in a routine diagnostic laboratory, and to compare its results with those obtained by a target-specific sequencing assay. Study Design We retrospectively analyzed 20 HIV-1 RNA/DNA samples from six individuals infected with different subtypes (A1-like, B, CRF-02, G, H) and followed at Caen University Hospital between 2018–2022. HIV-1 WGS was performed in five overlapping fragments using the DeepChek® Whole Genome HIV-1 Genotyping kit and sequenced on an Illumina iSeq100 platform. Results were compared to previous genotypes obtained by a CE-IVD target-specific kit. Results WGS achieved complete genome coverage for 18/20 samples, with subtype assignments consistent with patient history. The assay detected both majority (≥20%) and minority (3–20%) resistance mutations, including gp120 S375T and M434I associated with Fostemsavir resistance. Concordance with target-specific sequencing was high for pol regions, with WGS providing additional data on env and gag polymorphisms. Conclusions HIV-1 WGS is feasible in a hospital diagnostic laboratory and provides comprehensive resistance profiling, including detection of minority variants and novel target site polymorphisms. Its implementation can enhance therapeutic decision-making in the context of evolving antiretroviral landscapes.
No takes yet. Share an insight, caveat, or question.
Moriceau et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: